Mesoblast (MESO) Receivables - Other (2017 - 2026)
Mesoblast (MESO) posted Receivables - Other of $18.0 million for Q4 2024, up 498.53% sequentially from $3.0 million in Q4 2023, and up 498.53% YoY from $3.0 million in Q1 2024.
Powered by 
Analysis
Mesoblast (MESO) Receivables - Other (2017 - 2026) Analysis & Trends
Mesoblast has reported Receivables - Other for 6 years, with the latest figure at $18.0 million in Q4 2024.
- Quarterly Receivables - Other rose 498.53% year-over-year to $18.0 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $18.0 million (up 498.53% YoY) and the FY2019 annual result came in at $1.5 million, up 143.9% from the prior year.
- Receivables - Other climbed to $18.0 million in Q4 2024 per MESO's latest filing, from $3.0 million in the prior quarter.
- Over five years, Receivables - Other peaked at $18.0 million in Q4 2024 and troughed at $894000.0 in Q4 2022.
- A 3-year average of $5.7 million and a median of $2.0 million in 2023 frame the typical range for Receivables - Other.
- The sharpest annual moves came in 2023 and 2024: Receivables - Other surged 235.57% in 2023, then jumped 498.53% in 2024.
- Over 3 years, Receivables - Other stood at $894000.0 in 2022, then soared by 235.57% to $3.0 million in 2023, then surged by 498.53% to $18.0 million in 2024.
- According to Business Quant data, Receivables - Other over the past three periods registered $18.0 million, $3.0 million, and $1.0 million for Q4 2024, Q4 2023, and Q1 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Mesoblast | 2.24 Bn | 2.14 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1,000.00 |
| Dec 31, 2025 | 28.03 Mn |
| Jun 30, 2025 | 190,000.00 |
| Dec 31, 2024 | 3.06 Mn |
| Jun 30, 2024 | 6.78 Mn |
| Jun 30, 2019 | 1.50 Mn |
| Mar 31, 2019 | 134,000.00 |
| Dec 31, 2018 | 93,000.00 |
| Sep 30, 2018 | 242,000.00 |
| Jun 30, 2018 | 615,000.00 |
| Mar 31, 2018 | 1.01 Mn |
| Dec 31, 2017 | 1.47 Mn |
| Sep 30, 2017 | 196,000.00 |
| Jun 30, 2017 | 698,000.00 |